A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

NCT02614794 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

612

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 Positive Breast Cancer

Interventions

DRUG: tucatinib
DRUG: capecitabine
DRUG: trastuzumab
DRUG: placebo

Sponsor

Seagen Inc.